Calithera Biosciences Inc. (NASDAQ:CALA)’s share price dropped 3.1% during trading on Thursday . The stock traded as low as $3.61 and last traded at $3.69, with a volume of 184,954 shares changing hands. The stock had previously closed at $3.81.

CALA has been the topic of a number of research analyst reports. Wells Fargo & Co. reiterated a “buy” rating on shares of Calithera Biosciences in a research report on Thursday, May 12th. Zacks Investment Research upgraded Calithera Biosciences from a “hold” rating to a “buy” rating and set a $6.50 target price on the stock in a research report on Tuesday, March 22nd. JMP Securities reiterated a “buy” rating on shares of Calithera Biosciences in a research report on Wednesday, June 8th. Finally, JPMorgan Chase & Co. decreased their target price on Calithera Biosciences from $20.00 to $12.00 and set a “market outperform” rating on the stock in a research report on Wednesday, March 9th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Calithera Biosciences currently has a consensus rating of “Buy” and an average target price of $10.48.

The firm has a 50 day moving average of $4.60 and a 200 day moving average of $5.46. The company’s market cap is $68.43 million.

Calithera Biosciences (NASDAQ:CALA) last announced its quarterly earnings results on Tuesday, May 10th. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.47) by $0.05. Equities analysts predict that Calithera Biosciences Inc. will post ($2.15) EPS for the current fiscal year.

Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.